FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016285888> ?p ?o ?g. }

• W2016285888 endingPage "1034" @default.
• W2016285888 startingPage "1025" @default.
• W2016285888 abstract "The efficacy of radioembolisation for the treatment of liver tumours depends on the selective distribution of radioactive microspheres to tumorous tissue. The distribution of holmium-166 ((166)Ho) poly(L-lactic acid) microspheres can be visualised in vivo by both single-photon-emission CT (SPECT) and MRI. In this phase 1 clinical trial, we aimed to assess the safety and the maximum tolerated radiation dose (MTRD) of (166)Ho-radioembolisation in patients with liver metastases.Between Nov 30, 2009, and Sept 19, 2011, patients with unresectable, chemorefractory liver metastases were enrolled in the Holmium Embolization Particles for Arterial Radiotherapy (HEPAR) trial. Patients were treated with intra-arterial (166)Ho-radioembolisation in cohorts of three patients, with escalating aimed whole-liver absorbed doses of 20, 40, 60, and 80 Gy. Cohorts were extended to a maximum of six patients if dose-limiting toxicity occurred. Patients were assigned a dose in the order of study entry, with dose escalation until dose-limiting toxicity was encountered in at least two patients of a dose cohort. Clinical or laboratory toxicities were scored according to the National Cancer Institute's Common Terminology Criteria for Adverse Events version 3.0. The primary endpoint was the MTRD. Analyses were per protocol. This study is registered with ClinicalTrials.gov, number NCT01031784.15 patients underwent (166)Ho-radioembolisation at doses of 20 Gy (n=6), 40 Gy (n=3), 60 Gy (n=3), and 80 Gy (n=3). Mean estimated whole-liver absorbed doses were 18 Gy (SD 2) for the 20 Gy cohort, 35 Gy (SD 1) for the 40 Gy cohort, 58 Gy (SD 3) for the 60 Gy cohort, and 73 Gy (SD 4) for the 80 Gy cohort. The 20 Gy cohort was extended to six patients because of the occurrence of dose-limiting toxicity in one patient (pulmonary embolism). In the 80 Gy cohort, dose-limiting toxicity occurred in two patients: grade 4 thrombocytopenia, grade 3 leucopenia, and grade 3 hypoalbuminaemia in one patient, and grade 3 abdominal pain in another patient. The MTRD was identified as 60 Gy. The most frequently encountered laboratory toxicities (including grade 1) were lymphocytopenia, hypoalbuminaemia, raised alkaline phosphatase, raised aspartate aminotransferase, and raised gamma-glutamyltransferase, which were all noted in 12 of 15 patients. Stable disease or partial response regarding target lesions was achieved in 14 of 15 patients (93%, 95% CI 70-99) at 6 weeks and nine of 14 patients (64%, 95% CI 39-84) at 12 weeks after radioembolisation. Compared with baseline, the average global health status and quality of life scale score at 6 weeks after treatment had decreased by 13 points (p=0·053) and by 14 points at 12 weeks (p=0·048). In all patients, technetium-99m ((99m)Tc)-macro-aggregated albumin SPECT, (166)Ho scout dose SPECT, and (166)Ho treatment dose SPECT showed similar patterns of the presence or absence of extrahepatic deposition of activity.(166)Ho-radioembolisation is feasible and safe for the treatment of patients with unresectable and chemorefractory liver metastases and enables image-guided treatment. Clinical (166)Ho-radioembolisation should be done with an aimed whole-liver absorbed dose of 60 Gy." @default.
• W2016285888 created "2016-06-24" @default.
• W2016285888 creator A5005933856 @default.
• W2016285888 creator A5010167819 @default.
• W2016285888 creator A5020615830 @default.
• W2016285888 creator A5025180096 @default.
• W2016285888 creator A5036824467 @default.
• W2016285888 creator A5064157733 @default.
• W2016285888 creator A5065014010 @default.
• W2016285888 creator A5090299971 @default.
• W2016285888 date "2012-10-01" @default.
• W2016285888 modified "2023-10-10" @default.
• W2016285888 title "Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study" @default.
• W2016285888 cites W1509861992 @default.
• W2016285888 cites W1811288600 @default.
• W2016285888 cites W1965154609 @default.
• W2016285888 cites W1966707043 @default.
• W2016285888 cites W1969529822 @default.
• W2016285888 cites W1972423598 @default.
• W2016285888 cites W1979065577 @default.
• W2016285888 cites W1984715437 @default.
• W2016285888 cites W1999553451 @default.
• W2016285888 cites W2010920397 @default.
• W2016285888 cites W2013057709 @default.
• W2016285888 cites W2017938115 @default.
• W2016285888 cites W2019607817 @default.
• W2016285888 cites W2025540628 @default.
• W2016285888 cites W2036806360 @default.
• W2016285888 cites W2038197429 @default.
• W2016285888 cites W2043704659 @default.
• W2016285888 cites W2043860680 @default.
• W2016285888 cites W2049297875 @default.
• W2016285888 cites W2057133982 @default.
• W2016285888 cites W2061634373 @default.
• W2016285888 cites W2070339511 @default.
• W2016285888 cites W2089561005 @default.
• W2016285888 cites W2107146466 @default.
• W2016285888 cites W2109136089 @default.
• W2016285888 cites W2110340629 @default.
• W2016285888 cites W2112016834 @default.
• W2016285888 cites W2116960604 @default.
• W2016285888 cites W2125058077 @default.
• W2016285888 cites W2144599373 @default.
• W2016285888 cites W2156781004 @default.
• W2016285888 cites W2161107000 @default.
• W2016285888 cites W2167430414 @default.
• W2016285888 doi "https://doi.org/10.1016/s1470-2045(12)70334-0" @default.
• W2016285888 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22920685" @default.
• W2016285888 hasPublicationYear "2012" @default.
• W2016285888 type Work @default.
• W2016285888 sameAs 2016285888 @default.
• W2016285888 citedByCount "132" @default.
• W2016285888 countsByYear W20162858882012 @default.
• W2016285888 countsByYear W20162858882013 @default.
• W2016285888 countsByYear W20162858882014 @default.
• W2016285888 countsByYear W20162858882015 @default.
• W2016285888 countsByYear W20162858882016 @default.
• W2016285888 countsByYear W20162858882017 @default.
• W2016285888 countsByYear W20162858882018 @default.
• W2016285888 countsByYear W20162858882019 @default.
• W2016285888 countsByYear W20162858882020 @default.
• W2016285888 countsByYear W20162858882021 @default.
• W2016285888 countsByYear W20162858882022 @default.
• W2016285888 countsByYear W20162858882023 @default.
• W2016285888 crossrefType "journal-article" @default.
• W2016285888 hasAuthorship W2016285888A5005933856 @default.
• W2016285888 hasAuthorship W2016285888A5010167819 @default.
• W2016285888 hasAuthorship W2016285888A5020615830 @default.
• W2016285888 hasAuthorship W2016285888A5025180096 @default.
• W2016285888 hasAuthorship W2016285888A5036824467 @default.
• W2016285888 hasAuthorship W2016285888A5064157733 @default.
• W2016285888 hasAuthorship W2016285888A5065014010 @default.
• W2016285888 hasAuthorship W2016285888A5090299971 @default.
• W2016285888 hasConcept C121608353 @default.
• W2016285888 hasConcept C126322002 @default.
• W2016285888 hasConcept C126838900 @default.
• W2016285888 hasConcept C197934379 @default.
• W2016285888 hasConcept C203092338 @default.
• W2016285888 hasConcept C2776231280 @default.
• W2016285888 hasConcept C2777793932 @default.
• W2016285888 hasConcept C29730261 @default.
• W2016285888 hasConcept C2989005 @default.
• W2016285888 hasConcept C509974204 @default.
• W2016285888 hasConcept C535046627 @default.
• W2016285888 hasConcept C71924100 @default.
• W2016285888 hasConcept C72563966 @default.
• W2016285888 hasConceptScore W2016285888C121608353 @default.
• W2016285888 hasConceptScore W2016285888C126322002 @default.
• W2016285888 hasConceptScore W2016285888C126838900 @default.
• W2016285888 hasConceptScore W2016285888C197934379 @default.
• W2016285888 hasConceptScore W2016285888C203092338 @default.
• W2016285888 hasConceptScore W2016285888C2776231280 @default.
• W2016285888 hasConceptScore W2016285888C2777793932 @default.
• W2016285888 hasConceptScore W2016285888C29730261 @default.
• W2016285888 hasConceptScore W2016285888C2989005 @default.
• W2016285888 hasConceptScore W2016285888C509974204 @default.
• W2016285888 hasConceptScore W2016285888C535046627 @default.
• W2016285888 hasConceptScore W2016285888C71924100 @default.

• next